Name	Current Price - Today's Change	Market Cap
JOHNSON & JOHNSON (JNJ)	$62.76 - $0.39(0.63%)	172.83 B
PFIZER INC (PFE)	$17.88 - $0.04(0.22%)	144.93 B
NOVARTIS AG ADS (NVS)	$53.58 - $0.50(0.94%)	120.96 B
MERCK & COMPANY; INC. (MRK)	$36.47 - $0.12(0.33%)	113.83 B
SANOFI-AVENTIS ADS (SNY)	$36.29 - $0.38(1.06%)	93.43 B
ABBOTT LABORATORIES (ABT)	$53.35 - $0.00(0.00%)	83.48 B
ASTRAZENECA PLC (AZN)	$44.11 - $0.98(2.27%)	62.34 B
AMGEN INC (AMGN)	$57.21 - $0.25(0.44%)	58.38 B
TEVA PHARMACEUTICAL LTD (TEVA)	$57.10 - $0.18(0.32%)	51.77 B
BRISTOL-MYERS SQUIBB CO (BMY)	$24.25 - $0.29(1.21%)	47.48 B

STOCK ANALYSIS

Pfizer Feeling Frisky (PFE, LLY, FRX, GSK)
Investors are worried about Lipitor's patent running out, but Pfizer has many other ways to give your portfolio a r...

UK's Global Footprint Stocks (AZN, GOLD, GSK, RIO)
Looking across the pond at the UK, one can't help but be attracted to some of the opportunities.

H1N1 Vaccines Finally Bearing Revenue (AZN, NVS, SNY, GSK, BAX)
Investors lost interest in swine flu vaccine stocks, like AZN and GSK, before they had a chance to enjoy any revenue.

McKesson Riding High On H1N1 (MCK, GSK, BAX, NVS, AZN)
Investors should keep a close watch on drug distribution firm McKesson's stock.

Four High-Flying Pharmaceutical Companies (GSK, VNDA, BCRX, OGXI, HGSI, NVS)
A look at some of the best-performing stocks year to date - up anywhere from 400% to 2000%.

View All Stock Analysis

GSK RELATED HEADLINES

Believe In The Market's Healthy Skepticism
Nobody is giving this bull market any credit, but that's good news. Here are some stocks you should buy.
Forbes.com 2/5/2010

Pfizer Feeling Frisky (PFE, LLY, FRX, GSK)
Investors are worried about Lipitor's patent running out, but Pfizer has many other ways to give your portfolio a rise.
at Investopedia Advisor 2/4/2010

Ten Questions About High Cholesterol
The biggest heart risk factor still mystifies top scientists. Here's what you need to know.
Forbes.com 2/3/2010

The Pharma Marketing Hydra
Just because academic centers limit how much drug companies pay doctors doesn't mean high-paid speakers will go away.
Forbes.com 1/28/2010

Big Pharma's Best Chief Steps Down
Novartis' Dan Vasella has done better than his peers. Now he is handing over the reins.
Forbes.com 1/26/2010

Doubts Build On Glaxo's Antiaging Drugs
The drugmaker bet $720 million on drugs based on the wine-ingredient resveratrol. New studies suggest that the drugs won't work.
Forbes.com 1/26/2010

View All Headlines